United in Strength, Building Brilliance Together – Shenzhen Cell Valley 2023 Mid-Level Management Summary Meeting Successfully Held

As the new year begins, everything is renewed. On January 5, 2024, Chairman Shi Yuanyuan presided over the Shenzhen Cell Valley 2023 Mid-Level Management Summary Meeting. Attendees included Chief Scientist Wang Jianxun, Deputy General Manager Xiang Hua, Deputy General Manager Tang Xiaomeng, Shenzhen Cell Valley Production and R&D Director and Executive President of wholly-owned subsidiary Junhou Bio Feng Yaru, Head of R&D Zhao Lijun, Quality Management Director Zhang Xuefeng, Deputy Quality Management Director Li Rongyou, Head of Marketing Sun Rui, Deputy Head of Marketing Yang Jianglong, Head of General Affairs Shi Yunzhu, Assistant to the Chairman Wei Zheng, and Director of the General Administration Office Luan Zhishi. The entire mid-level and senior management team came together to review the achievements of the past year, summarize lessons learned, identify areas for improvement, and outline goals for the coming year.

Looking back on the journey of the past year and ahead to the new path before us, 2023 was a year of overcoming difficulties and facing challenges. During this exploratory period, Shenzhen Cell Valley maintained firm confidence, kept its sights set on its goals, and forged ahead through obstacles, creating a year marked by remarkable breakthroughs and accomplishments. During the meeting, department heads presented summaries of their respective departments' performance in 2023, progress made, and issues encountered, and reported on their work plans and objectives for the coming year.

Subsequently, Chairman Shi Yuanyuan provided a comprehensive review of the company's performance in 2023, offering an in-depth analysis of the achievements of each department and fully affirming the relentless efforts of the Cell Valley team throughout the year. He also clarified the key priorities for 2024. Chairman Shi noted that over the past year, the company had overcome both subjective and objective challenges, innovated through exploration, and developed through innovation, steadily meeting performance targets and work objectives. The teams at Shenzhen Cell Valley, its wholly-owned subsidiaries Junhou Bio and Jing-Shen Cell Valley, have gradually grown and now achieve efficient collaboration across departments. Going forward, the company should place greater emphasis on corporate culture development, team building, research and innovation, and market expansion; continue to convey the corporate cultural philosophy of "Cells benefit all, genes create the future" and shape the corporate image; stimulate employee creativity to build highperforming teams; continuously optimize processes and upgrade technologies in the face of both challenges and opportunities in the cell and gene therapy industry; closely follow market demands to adjust and develop product directions, enhancing the company's core competitiveness; and strengthen cooperation and exchanges with government, enterprises, universities, research institutes, and hospitals. Through strategic partnerships, the company will continue to expand sales channels, generate economic benefits, and steadily achieve sustainable development.

"United in strength, building brilliance together." In 2023, the Cell Valley team upheld the spirit of perseverance and resilience, forging ahead through challenges. In 2024, we commit to our original aspirations and strive for excellence. In the new year, all employees of Shenzhen Cell Valley will continue to work hand in hand, contributing to the company's leapfrog development and making positive contributions to the highquality development of the cell and gene therapy industry.